Drugs / IPL344
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03652805 | Aug 2018 → Jan 2026 | amyotrophic lateral sclerosis | Immunity Pharma Ltd. | Suspended | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03755167 | Dec 2018 → Jan 2027 | amyotrophic lateral sclerosis | Immunity Pharma Ltd. | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPL344 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03652805 ↗ |
| Known as | Stressin 1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650479 ↗ |
| Route | Intravenous | “IPL344 will be administered Intravenously on a daily basis.” NCT03652805 ↗ |